Michael H Kroll
Overview
Explore the profile of Michael H Kroll including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
586
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel R, Pal K, Ahmed S, Kuban J, Patel M, Shah K, et al.
Cardiovasc Intervent Radiol
. 2024 Mar;
47(5):556-566.
PMID: 38548981
Purpose: Venous thromboembolism (VTE) is a major contributor to the mortality of cancer patients. Mechanical thrombectomy (MT) is an endovascular technique that physically removes a thrombus without thrombolytics. The purpose...
2.
Kroll M
Hematology Am Soc Hematol Educ Program
. 2023 Dec;
2023(1):209-215.
PMID: 38066867
Immune checkpoint inhibitors are a class of antineoplastic therapies that unleash immune cells to kill malignant cells. These medications commonly cause immune-related adverse effects due to activated adaptive and innate...
3.
Font C, Gomez-Mesa J, Lopez-Nunez J, Calderon C, Galindo-Coral S, Wu C, et al.
Support Care Cancer
. 2023 Oct;
31(10):615.
PMID: 37801086
Purpose: Therapy for cancer-associated venous thromboembolism (VTE) includes long-term anticoagulation, which may have substantial impact on the health-related quality of life (HRQL) of patients. We assessed patient-reported outcomes to characterize...
4.
Ullah F, Song J, Rojas Hernandez C, Kroll M, Escalante C, Toale K
Oncologist
. 2023 Jun;
28(11):e1005-e1016.
PMID: 37310796
Background: Patients with gastrointestinal cancer (GICA) are at high risk for venous thromboembolism (VTE). Data from randomized clinical trials in cancer-associated VTE suggest that direct oral anticoagulants (DOACs) conferred similar...
5.
Li A, De Las Pozas G, Andersen C, Nze C, Toale K, Milner E, et al.
Am J Hematol
. 2023 Apr;
98(7):1052-1057.
PMID: 37067102
Venous thromboembolism (VTE) is a significant complication for cancer patients undergoing systemic therapy. We performed an independent external validation for a recently derived and validated a novel electronic health record...
6.
7.
Kroll M, Rojas-Hernandez C, Yee C
Blood
. 2021 Oct;
139(25):3594-3604.
PMID: 34610113
Immune checkpoint inhibitors are a class of antineoplastic therapies that unleash immune cells to kill malignant cells. There are currently 7 medications that have been approved by the US Food...
8.
Hill A, Elakkad A, Kuban J, Sabir S, Odisio B, Huang S, et al.
Abdom Radiol (NY)
. 2020 Apr;
45(9):2886-2894.
PMID: 32314004
Purpose: Partial splenic artery embolization (PSAE) has shown promise in increasing platelet counts in cancer patients with hypersplenism-related thrombocytopenia. The purpose of this study was to identify response predictors and...
9.
10.
Chen L, Bose P, Cruz N, Jiang Y, Wu Q, Thompson P, et al.
Blood
. 2018 Sep;
132(21):2249-2259.
PMID: 30254130
Ibrutinib is highly efficacious and used at 420 mg/d for treatment of chronic lymphocytic leukemia (CLL). We previously demonstrated a decline in Bruton's tyrosine kinase (BTK) protein levels in CLL...